aliss adventur mycobacteria-land
promis opportun novel orphan area unmet need
outperform vs nbi thank strong phase
result ali ntm lung infect initi data support use
us refractori patient popul assum ali launch
around end price near top end anti-infect
therapi gross annual stori shift focu
commerci opportun see long-term case upsid clinic
profil develop await firmer sens drug deploy
clinician earli day launch
ali durat therapi still determin model
patient ali respond remain therapi month
remain receiv month treatment updat phase
result expect late earli could show addit
convers past month lead longer averag cours ali
could expand peak sale project
could similar upsid possibl retreat relaps patient
long-term expect develop ali chronic ntm mainten
ali like focu refractori patient pend addit data
long-term aim posit ali front-lin mainten
settingsw forese ali potenti receiv initi broad label
expect fda adcom clarifi possibl howev given
project high price therapi launch expect payer may seek
addit data support front-lin uptak await greater clariti
compani timelin support goal
valuationiniti coverag neutral rate tp
valuat base blend dcf project risk thesi includ
disappoint clinic trial updat commercial/regulatori setback
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
biopharmaceut compani focus address rare
pulmonari diseas lead product candid ali current
phase treatment adult patient treatment refractori
ntm lung diseas caus
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base probabl
success ali treatment ntm
assum initi durat therapi month
grey sky valuat base probabl
success ali treatment ntm
assum averag durat therapi month
 close
initi coverag neutral rate target price base
strong phase data think well posit file nda ali ntm
late like acceler review fda approv year-end
event transit investor focu ali commerci opportun
refractori ntm popul potenti long-term expans front-lin use
and/or chronic mainten therapi patient prior ntm infect
think ali approv larg bake current stock price think drug
phase profil support strong price gross annual top end anti-
infect refractori ntm popul estim peak penetr
set long commerci life generic inhal drug carri higher
degre difficulti ali ip extend given
approv drug indic requir up-front clinician educ expect
take year achiev peak market penetr
fda adcom expect illustr breadth initi label
could
trajectori see sever
opportun expand market ali includ entri high-
preval japanes market may follow us approv year
explor self-promot ali japan success strategi
orphan diseas compani past use ali front-lin set await
updat compani clinic develop plan ali chronic use
ali part mainten regimen patient post-resolut ntm
await greater clariti path sourc upsid see expect durat
therapi payer support variou market scenario signific valu driver
visibl like improv time addit clinic data exampl
model ali expand chronic mainten role eventu constitut
peak sale assumpt us global
aliss
credit suiss biotech short-term outlook think investor focu next
approxim six month ali nda file expect
commerci launch increment data provid compani earli januari suggest
non-convert month may benefit treatment believ
matur data could bolster investor optim
credit suiss biotech long-term outlook think ali approv late
larg expect model probabl success point potenti fda
adcom meet provid clue breadth initi label expect could
ramif initi market uptak access trend commerci think
market focu abil extend durat treatment key driver
credit suiss biotech outlook think could attract
acquisit candid larger compani exist pulmonolog rare diseas
franchis attract aliss strong clinic profil long project commerci
lifespan serv orphan area unmet need low competit ali fulli
unencumb envis strateg buyer could leverag exist commerci
expertis navig commerci payer environ drive global adopt
ali demonstr meaning efficaci refractori patient
popul patient cultur convert compar
placebo arm result tough-to-treat patient
popul suggest fda amen approv
fda may want long-term data demonstr
sustain effect follow convers approv ali
could delay approv year
base discuss expert manag believ ali high likelihood approv given compel
efficaci tolerable/saf profil expect approv come late allow commerci sale start late
think advisori committe probabl panel discuss potenti influenc
ii ali durat therapi
updat result phase trial support continu
use ali patient dont convert six month
treatment patient treat least
month even convert
isnt compel data suggest continu use
ali patient dont convert six month treatment
convey clinic benefit given patient convert
patient use ali roughli six month
model initi durat therapi month month non-respond month respond
patient didnt convert month ali convert follow anoth month therapi result appear
meaning exact interpret challeng one hand control group patient convert trial
hand averag patient trial year prior enrol matur phase data
would use assum payer scrutini could high use unproven situat sinc expect ali high-pric
broadli adopt use
refractori patient sinc ali effect fairli rapid onset
efficaci refractori patient clinician seek use ali
earlier broader patient popul ali may also use
chronic help prevent recurr ntm
ali like effect front-lin mainten
therapi access problemat given potenti
discuss expert suggest ali strong uptak among refractori patient payer pushback expect
manag set owe lack treatment altern howev even confirmatori trial front-lin
mainten therapi ali may difficulti penetr broader opportun expect ali price in-lin
cayston tobramycin cf expect payer manag off-label access highlight import initi fda label
arikayc
arikayc
ali ntm nda submiss
ali ntm
ali chronic pa
ncfbe
ncfbe
pah
insm ali appear pois first fda
drug approv treatment ntm infect
posit phase result strong regulatori design suggest fda
construct approv
ali well posit product choic treatment refractori ntm
year come
updat phase data futur clinic trial could illumin breadth
insm ali afford patient access amikacin without
toler safeti issu limit use efficaci iv therapi
develop amikacin liposom inhal suspens ali
treatment refractori ntm non-tubercul mycobacteri lung diseas caus
mycobacterium avium complex ntm often debilit lung infect occur
patient pulmonari comorbid copd pulmonari fibrosi compani
estim ntm diseas rapidli grow annual approxim
patient infect caus refractori standard antibiot
regimen believ diseas demograph suggest potenti us
market opportun appendix inform ntm
posit result suggest high likelihood ali approv
report posit phase trial result ali septemb pivot trial
enrol adult patient random ali daili guidelin base therapi
across site countri includ studi patient need
fail least six month multi-drug regimen primari endpoint studi
percentag cultur convers defin three consecut
neg sputum cultur collect monthli treatment arm rel control
month six endpoint includ chang month six time cultur
convers mean chang baselin month six st georg
immedi enrol
aliss phase top-lin result demonstr higher faster clearanc
compar guideline-bas therapi patient treatment arm convert
month six compar control group patient gbt-onli
arm took longer convert compar ali plu recal
patient refractori six month treatment enrol studi
context result even meaning improv observ
convert patient though studi miss secondari endpoint
analysi popul
convers month
time convers
improv time convert
updat result releas januari reinforc aliss efficaci first look
ole found similar convers rate patient nave ali seen
month appear convey addit clinic benefit patient didnt convert
month ali convert follow anoth month therapi durabl
cultur convers also appear compel ali gbt patient ins-
trial previous convert remain cultur neg month cessat
treatment context ntm natur histori studi suggest patient
relaps reinfect within year data illumin percentag patient
relaps vs acquir new infect could clarifi abil ali retreat
patient
expert found ali reason safeti profil percentag patient
treatment-emerg advers event consist across trial arm importantli
increas hear loss renal impair seen ali cohort symptom
commonli seen patient receiv iv amikacin rate advers event higher
ali cohort accord compani advers event gener occur
first month treatment increas rate advers event ali cohort may
account higher discontinu rate vs origin result
discontinu ole
respiratori thorac mediastin
infect infest
kol specul individu treatment less frequent dose
commenc therapi could reduc frequenc advers event howev
yet sure much improv toler result clinician judgement
practic
acceler regulatori path us expect allow approv
prior complet phase
owe high unmet need new treatment ntm especi refractori ntm
expect insm submit applic fda acceler approv late
potenti approv late final full approv may
conting upon success complet on-going phase program note
receiv orphan drug design breakthrough therapi design btd
qualifi infecti diseas product qidp support bia
fda appear highli interest facilit develop therapeut combat
ntm given highli favor read phase primari endpoint assign
high probabl success aliss approv base exist data
insm appear pois success captur market share
potenti strong patient uptak
appear way toward success launch ali posit
bias manag underli initi abl drive commerci
infrastructur
profit insm plan util sale repres target
health care provid treat major patient market research
suggest physician gener pulmonologist infecti diseas
specialist treat ntm patient target approach market
penetr drive strong long-term revenu growth fairli effici
ou strategi ration focu geographi highest ntm
diseas burden emphas ex-u product develop
territori japan carri rel higher rate ntm infect
insm estim refractori ntm infect
japan vs eu compani indic would
consid ad commerci partner japan comfort continu
advanc product potenti launch independ expect insm
engag japanes regul cours next year think
compani may posit submit approv applic closer end
note japanes patient includ phase
convert studi histori success orphan drug launch
us/eu compani japan recent year would see go-alon strategi
higher risk/reward albeit justifi one given market potenti bulk
long-term ou revenu assumpt driven sale japan
strong patent exclus protect expect ali strong cash
flow gener mani year come model ali sale
qidp orphan design expect ali grant year
regulatori exclus us
competit front awar drug develop late-
stage clinic test refractori ntm patient patient today occasion
use intraven inhal amikacin treat difficult case ntm ali heavili
advantag clinic data set prove efficaci treatment effect anecdot
form amikacin along demonstr toler safeti advantag
iv amikacin clinician spoke echo sentiment indic
would overwhelmingli prescrib ali form amikacin drug
assum gross price /yr /month insm note refractori ntm
patient difficult manag like requir multipl physician visit annual
compani present data show ntm infect add cost
treat underli condit lung cancer ipf use price comp
consider includ
gilead cayston wac price cayston inhal
aztreonam approv fda use cf patient
pseudomona aeruginosa gilead abl price cayston gross price
six month therapi cayston administ
increment everi month
novartiss tobi inhal system wac price
tobi inhal system prescrib cf patient aeruginosa
therapi administ cycl everi month
atu price ali franc upward euros/yr
success ali first drug approv treat refractori ntm strong
efficaci safeti date suggest ali gener strong sale commerci
sale model global us model
peak penetr assumpt refractori ntm popul
complianc rate accommod discontinu due toler
lack respons patient
durat therapi month averag initi assum respons
rate treatment month non-respond remain therapi
month
ip/model durat model ali sale ip extend
least assum addit three year termin valu dcf
account possibl new ip in-lin view drug-devic
combin challeng generic
potenti upsid expect
long-term explor opportun expand label direct
expand usag ali treatment ntm
anticip compani investig ali part front-lin regimen treat
ntm anoth path expect insm investig use ali long-
term monotherapi prevent recurr ntm diseas patient success
achiev cultur convers cure see logic approach expect
drug ali proven efficaci well-control phase trial would like
confer benefit front-lin mainten set well though note
expans market refractori ntm patient
also suggest explor potenti expand use ali
indic one indic ali explor ntm caus abscessu
would natur fit compani consult note difficulti erad
ntm-caus speci note limit sampl size ali less
effect set compar ntm phase trial
expect insm make announc potenti clinic path forward
timelin approach addit pipelin opportun
cover appendix
charl martineau pm univers toronto figur ali ntm revenu build
incid ntm lung diseas
ntm caus
preval refractori ntm
year market entranc
year market penetr
incid ntm lung diseas
ntm caus
preval refractori ntm
year market entranc
year market penetr
arriv target price use blend valuat approach includ product-
base dcf dcf
dcf model assum discount rate standard discount rate late-stag
pre-commerci compani fulli dilut share million long-term oper
margin tax rate assign termin valu
reflect confid ali gener sale beyond assign
detail dcf compon includ follow
second valuat scenario support target reflect
reduct sg reduct increas revenu
ali ntm
initi month therapi
probabl success
standard probabl success assumpt phase asset
phase asset phase asset asset nda/bla stage
slight adjust base histor probabl success specif diseas
categori standard mind assign follow probabl success
ali ntm line standard probabl success
assumpt reflect confid program light strong clinic
data indic approv therapi
blue sky valuat base probabl success ali
treatment ntm assum initi durat therapi
month month grey sky valuat base probabl
success ali treatment ntm assum
averag durat therapi month
regulatory/clin risk includ limit trial enrol delay poorly-
design studi
inadequ endpoint enough power neg
safety/efficaci signal neg dsmb/health author rule specif
lack cultur convers beyond month patient ali
emerg safeti issu ali
develop risk associ earlier stage asset
liquidity/fund difficulti develop candid
manufacturing/suppli risk includ limit suppli disrupt product
batch adher
contamin technic difficulti produc function complex molecul delay
construction/certif new facil inadequ lack materi
qualiti standard manufactur shutdown due
inabl manufactur suffici quantiti ali pipelin candid
meet clinic commerci demand
commerci risk includ limit lower expect adopt drug
target popul competit clinical/exist agent payor-impos access
access reimburs challeng ali
competit threat ntm space
price challeng ali
commercial/awar issu ali
million except share ep
loss incom tax
figur balanc sheet
million
cash equival
prepaid expens
current portion lt debt
total liabil sharehold equiti
million
depreci amort
chang oper assets/li
prepaid expens
accru exp
net cash use oper activ
purchas fix asset
sale fix asset
purchase/sal invest
net cash use invest activ
proce issuanc debt
repay debt
proce issuanc stock
repurchas stock
proce issuanc stock option
net cash provid financ activ
effect exchang rate
net increas decreas cash
begin period
end period
ntm sever impair qualiti life signific portion
patient refractori current treatment
nontubercul mycobacteri ntm lung diseas rare bacteri infect caus
inhal airborn mycobacteria class bacteria commonli found water
suppli soil river minim person-to-person transmiss diseas
typic occur elderli often patient underli comorbid
commonli includ copd bronchiectasi relat disord incid
diseas per preval patient us roughli
case caus mycobacterium avium complex
diagnosi ntm fairli straightforward chest imag use identifi ntm
underli form diseas cavitari diseas vs nodular diseas species-specif
skin antigen test may also use ntm suspect microbiolog evalu
requir confirm diagnosi diagnost consist least three separ
expector sputum mucu specimen obtain morn result
sputum test inconclus biopsi may necessari accord kol portion
patient asymptomat time diagnosi patient diseas found
screen ill
diseas sever vari patient symptomat symptom ntm includ
chronic recur cough sputum product fatigu dyspnea fever chest pain
weight loss rare instanc ntm lung diseas result structur lung damag
respiratori failur anecdot kol indic symptomat patient rare
leav home struggl simpl day-to-day activ
incid ntm grow year us expect
continu forese futur kol unsur preval grow
specul result grow elderli popul advanc
diagnost techniqu improv chest imag technolog clinician
theoriz rise preval could result fundament chang underli
environment factor event ntm grow issu among elderli patient
current standard care involv long-term antibiot patient
symptomat initi therapi typic involv cocktail approach includ
macrolid rifampin/rifabutin ethambutol and/or aminoglycosid
azithromycin
rifamycin rifampin
streptomycin amikacin
iv inhal
approxim ntm patient refractori treatment
patient may prescrib aminoglycosid streptomycin amikacin taken
sever month top exist therapi iv inhal aminoglycosid
shown effect howev plagu seriou safeti issu
iv amikacin associ elev rate ototox nephrotox
peloquin et al meanwhil inhal amikacin associ lower rate
ototox nephrotox challeng advers event profil make
titrat toler difficult olivi et al
ali phase trial enrol patient treatment refractori nontubercul
mycobacteri lung diseas patient trial random receiv
ali placebo daili day top on-going multidrug regimen
chang baselin semiquantit cultur result day
neg sputum cultur day day follow-up visit
sputum cultur convers end-of-studi follow-up visit
durabl sputum cultur convers safeti follow-up
stratif screen
patient cystic fibrosi
macrolid resist amikacin mutat po
pntm defin american thorac societi at
on-going at guidelines-bas multidrug treatment least month prior screen
persist posit cultur avium abscessu
less predict
clinic signific cardiac pulmonari hepat renal diseas
construct phase inform effect phase strategi
phase trial compani abl determin
primari endpoint phase trial rate sputum
cultur convers day ali gbt patient neg sputum
cultur compar control group kol spoke
found result signific recal studi enrol patient
refractori treatment therefor abl effect address ntm
patient meaning kol also comment lack statist
signific chang baselin sq score diminish
import result emphas chang sq score
less clinic meaning lack statist influenc endpoint
may result account one death treatment arm
unrel therapi
phase trial focu patient ntm trial found
avium patient receiv ali convert phase
compar control group meanwhil meaning differ
convers rate seen patient mycobacteria speci
phase trial exclud patient high amikacin
resist phase trial compani determin therapi
effect patient molecularly-determin amikacin
resist mutat greater milligrams/ml
figur ali phase efficaci treatment group
convers double-blind phase day
convers double-blind phase day
convers double-blind phase day
approxim patient treatment arm experienc least one treatment-
emerg advers event common advers event includ dysphonia
wheez ineffect pulmonari exacerb cf major advers
event mild moder natur higher proport seriou advers event
occur treatment arm vs
patient teae
number tae
patient seriou tae
patient tae lead discontinu
patient tae max sever
grade life-threaten disabl
infect pulmonari exacerb cf
elev ae profil contribut higher discontinu rate treatment
group patient ali cohort discontinu treatment doubl
blind phase studi discontinu control group
seven patient discontinu ali result safeti issu three
patient discontinu treatment due bronchiectasi exacerb two discontinu
treatment dyspnea
addit patient discontinu treatment open label extens
discontinu owe advers event six origin treatment arm
placebo cohort doubl blind phase
sever product earlier clinic develop includ ali chronic
pseudomona aeruginosa non-cf bronchiectasi non-cyst fibrosi
bronchiectasi pulmonari arteri hypertens describ
greater detail anticip inhal treprostinil long-act
version tyvaso may advanc phase studi
ali ntm
ali chronic pa
ncfbe
ncfbe
pah
appear mechanist intuit potenti improv
current treatment paradigm though still earli develop
develop oral inhibitor acquir astrazenica treat
non-cf bronchiectasi enzym respons activ neutrophil
serin proteas matur neutrophil recent evid suggest neutrophil
inflamm play role non-cf bronchiectasi diseas progress chalmer et
al therefor therapeut hypothesi inhibit
prevent activ neutrophil serin proteas neutrophil elastas proteinas
cathepsin therebi reduc inflamm
non-cf bronchiectasi progress condit character stretched-out air
tube estim patient age bronchiectasi us
sietz et al underli caus bronchiectasi often idiopath
case caus prior pneumonia copd tb autoimmun diseas
regardless underli caus patient exhibit chronic inflamm
airway due build-up biofilm bacteria particul matter inhal throughout
day time chronic inflamm result dilat thin
bronchial tube loss cilia symptom bronchiectasi includ hemoptysi
chronic cough sputum product short breath
diagnosi condit fairli straight forward may involv laboratori test
ct mdct scan chest radiograph clinician review hrct mdct
scan sign airway dilat build-up mucopurul plug debri
literatur suggest number diagnos case bronchiectasi
increas year exact reason increas unknown kol
specul advanc diagnost tool may partial explain find
gener underli scar damag bronchiectasi cant cure
therefor current treatment bronchiectasi involv prevent addit damag
airway inflamm reduct infect prevent bronchopulmonari
hygien sietz et al effect therapi exercis improv
respiratori muscl strength though often difficult patient popul airway
clearanc techniqu commonli use improv qualiti life addit
antibiot macrolid may use prevent exacerb howev clinician
must care prescrib antibiot risk develop drug-resist
infect lastli steroid anti-inflammatori drug may prescrib
therapi provid benefit kol express need addit agent
better manag diseas
phase studi healthi volunt found well toler
major safeti concern pk evid studi suggest potenti once-daili
dose addit demonstr evid dose-depend inhibit
commenc willow studi phase studi non-cf
bronchiectasi patient studi random double-blind placebo-
control studi expect enrol ncfbe patient includ within
four-week screen period treatment period patient
administ daili placebo primari endpoint effect
rel placebo time first pulmonari exacerb endpoint
includ rate exacerb qualiti life sputum neutrophil elastas
appear natur ali franchis
sourc possibl upsid
opinion believ nice complementari program
could provid upsid come year see attract program
therapi could address current unmet need indic
approv therapi patient ncfbe
estim patient could benefit therapi base
kol check could see revis estim base strength
clinic data
appear reason toler profil once-
daili oral administr could particular attract patient clinician
allow strong uptak
inhibit appear attract target
astrazenica demonstr statist signific improv
reduct inflammatori cytokin phase neutrophil elastas inhibitor trial
patient ncfbe
possibl commerci scale effici leverag insm
exist sale franchis leverag doctor network use
commerci ali
find program natur fit adopt conserv stanc
around program lack clinic data undevelop safeti profil
charl martineau pm univers toronto compani mention price
